DiaMedica Announces Research Collaboration with The Sanford Project, a Leading Type 1 Diabetes Research Center
November 08 2010 - 5:37PM
Marketwired
DiaMedica Inc., (TSX VENTURE: DMA) is pleased to announce the
commencement of a research collaboration with The Sanford Project,
a world leader in type 1 diabetes (T1D) research.
The Sanford Project is one of the initiatives established after
Denny Sanford's historic $400 M gift to Sanford Health in 2007. The
Project aims to cure T1D through the development of beta cell
regeneration therapies (the cells which produce insulin in the
pancreas). As announced on October 14, 2010, DiaMedica has shown
the ability of DM-99 to protect and increase beta cells by 1,277%,
making it a strong beta cell regeneration candidate. DiaMedica also
announced the in vivo validation of DM-199, its next generation
recombinant version of DM-99 on October 27, 2010.
DiaMedica will be working with Alexei Savinov MD/PhD, Associate
Scientist, The Sanford Project, who is a T1D beta cell regeneration
and autoimmunity expert using the non-obese diabetic (NOD) mouse
model. Dr. Savinov will be performing a definitive study in the NOD
mouse using DM-199. The study is designed to measure the dual
actions of DM-199, which are to protect/regenerate beta cells and
to halt the autoimmune attack.
"The encouraging DM-99 results prompted our interest to work
with DiaMedica and help to evaluate the potential of DM-199 in type
1 diabetes," stated Paul Burn, PhD, Todd & Linda Broin Chair
and Director of The Sanford Project.
"DiaMedica is delighted to be working with Dr. Savinov and The
Sanford Project", said Rick Pauls, CEO of DiaMedica. "This
collaboration will provide additional external validation of DM-199
by working with the prominent T1D research group at the Sanford
Project ", continued Mr. Pauls. "We believe DM-199 has the
potential to protect/proliferate beta cells and halt autoimmune
attacks which may result in a promising treatment for type I
diabetes patients."
About DiaMedica
DiaMedica is a biopharmaceutical company focused on developing
novel treatments for type 1 diabetes, type 2 diabetes and other
disorders. DiaMedica has completed two successful proof-of-concept
Phase II studies with DM-71 and DM-99, which demonstrated human
efficacy in lowering blood glucose levels in patients with type 2
diabetes.
DiaMedica's lead product DM-199 is a novel next generation
recombinant form of DM-99, which has shown the potential to
increase insulin sensitivity, reduce the autoimmune attack and
trigger proliferation of pancreatic beta cells, neural stem cells
and bone marrow cells. DiaMedica is listed on the TSX Venture
Exchange under the trading symbol "DMA". For further information
please visit www.diamedica.com.
About The Sanford Project
The Sanford Project is one of the four initiatives made possible
through Denny Sanford's transformational gift to Sanford Health in
2007. From its inception, The Sanford Project was "designed for
results." Sanford Health will combine clinical components of
patient care and science into one of the most promising and
fast-moving fields of research; regenerative medicine. Their goal
is to research and cure type 1 diabetes, all in pursuit of a
healthy future for our children. For further information please
visit www.sanfordproject.com.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively, the
"forward-looking statements"). These forward-looking statements
relate to, among other things, DiaMedica's objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, and can, in some cases, be identified by the use of words
such as "believe," "anticipate," "expect," "intend," "plan,"
"will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements. Specifically, this press release
contains forward-looking statements regarding matters such as, but
not limited to, the anticipated use of proceeds from the Offering,
management's assessment of DiaMedica's future plans, information
with respect to the advancement of DiaMedica's research and
development programs, and DiaMedica's other estimates and
expectations. These statements reflect management's current beliefs
and are based on information currently available to management.
Certain material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
uncertainties and risks related to our research and development
programs, the availability of additional financing, risks and
uncertainties relating to the anticipated use of proceeds, changes
in debt and equity markets, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, the cost and supply of raw materials, management
of growth, effects of insurers' willingness to pay for products,
risks related to regulatory matters and risks related to
intellectual property matters.
Additional information about these factors and about the
material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release, as well
as under the heading "Risk Factors" contained in DiaMedica's 2009
annual information form. DiaMedica cautions that the foregoing list
of important factors that may affect future results is not
exhaustive. When relying on DiaMedica's forward-looking statements
to make decisions with respect to DiaMedica, investors and others
should carefully consider the foregoing factors and other
uncertainties and potential events. Such forward-looking statements
are based on a number of estimates and assumptions, which may prove
to be incorrect, including, but not limited to, assumptions
regarding the availability of additional financing for research and
development companies, and general business and economic
conditions. These risks and uncertainties should be considered
carefully and investors and others should not place undue reliance
on the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, DiaMedica cannot
provide assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to
update or revise any forward-looking statement.
Contacts: DiaMedica Inc. Rick Pauls 204.477.7590 204.453.3745
(FAX) rpauls@diamedica.com www.diamedica.com Sanford Health Stacy
Jones Media Strategy Manager 605-328-7056
Stacy.jones@sanfordhealth.org www.sanfordproject.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024